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Background: Cold hypersensitivity in the hands and feet (CHHF) is one of the most common complaints among
Asians, especially in women. Korean red ginseng (KRG), which is a steamed form of Panax ginseng, has vasodilating
action in the peripheral vessels and increases blood flow under cold stress. However, few studies have evaluated
the effect of KRG on cold hypersensitivity.
Methods/Design: This trial is a randomized, double-blind, placebo-controlled trial in 80 CHHF patients. The trial will
be implemented at Kyung Hee University Hospital at Gangdong in Seoul, Korea. The participants will take KRG or a
placebo for eight weeks, after which they will be followed-up for four weeks. During the administration period, six
capsules of 500 mg KRG or placebo will be provided twice a day. The primary outcome is change of skin temperature
in the hands between baseline and after treatment. The secondary outcomes include the visual analogue scale scores
of cold hypersensitivity in the hands, change of skin temperature and the VAS scores of cold hypersensitivity in the feet,
the recovery rate of the skin temperature by the cold stress test of the hands, the distal-dorsal difference of the hands,
power variables of heart rate variability, and the 36-item short form health survey.
Discussion: This study is the first trial to evaluate the efficacy of KRG on CHHF by using infrared thermography. Our
study will provide basic evidence regarding CHHF.
Trial registration: CliniacalTrials.gov NCT01664156
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Distal-dorsal differenceBackground
Generally, cold hypersensitivity refers to the condition in
which patients feel excessively cold at low temperatures,
and cold hypersensitivity in the hands and feet (CHHF)
is one of the most common complaints among Asians,
especially in women. According to a previous study on
the genetic etiology of CHHF, the ratio of CHHF among
females to males was found to be approximately 3:2
[1]. In particular, the prevalence of CHHF in Japanese,
Korean and Chinese women is 54.3%, 25% and 20%, re-
spectively [2]. CHHF can lower the quality of life by* Correspondence: hanbang9597@hanmail.net
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reproduction in any medium, provided the orinterfering with daily activities and, according to Korean
medicine, may also be related to gynecological disorders
such as menstrual pain, irregular bleeding, leucorrhea and
infertility [3]. The known causes of CHHF are autonomic
nervous dysfunction, peripheral neuropathy, median neur-
itis, anemia and diabetes mellitus [4]. However, the patho-
physiology of CHHF remains unknown and a uniform
treatment has not been established.
The root of Panax ginseng C.A. Meyer has been used
worldwide for thousands of years for treatment of diverse
diseases including diabetes [5], postmenopausal symptoms
[6] and cancers [7]. Korean red ginseng (KRG) is a steamed
form of Panax ginseng, which suggests that chemical trans-
formation of active physiological properties occur involving
ginsenosides, polysaccharides, peptides and polyacetylenic. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Study flow chart. CHHF, cold hypersensitivity in the
hands and feet; KRG, Korean red ginseng.
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changes, KRG acquires additional physiological activities.
Steaming ginseng at temperatures over 100°C, results in
the production of the gisenosides Rg3 and Rg5, which are
not present in raw ginseng. Moreover, steamed ginseng is
more potent at inducing endothelium-dependent vasodila-
tion and radical-scavenging [9].
Many studies have suggested that KRG benefits vascu-
lar functions. KRG and its ginsenosides had vasodilating
action on peripheral vessels and increased the blood flow
under cold stress in animal experiments [10]. The ginse-
nosides isolated from KRG have been reported to cause
vasodilation in an endothelium-dependent and nitric
oxide- (NO-) mediated manner in a rabbit model [11].
Especially, the ginsenoside Rg3 was proven to inhibit
vascular contraction as a consequence of NO production
in a rat in vitro and in vivo [12]. Besides, in humans,
KRG improved the vascular endothelial dysfunction in
patients with hypertension through increasing synthesis
of NO [13]. In addition, according to a randomized, con-
trolled, double-blind trial, KRG was proven to improve
arterial stiffness as measured by augmentation index
[14]. According to Korean medicine, KRG is considered
to have a warm quality and is used as a tonic to invigor-
ate the body and enhance the ‘Qi’, which subsequently
improves blood flow [15].
The vasodilating action and the warm quality of KRG
provide a basis for its potential efficacy on CHHF. How-
ever, only one clinical trial has evaluated the effect of KRG
on CHHF [16]. In the previous trial, the participants were
divided into three groups that received KRG, placebo or ni-
fedipine (a vasodilator). The participants then submerged
their hands in cold water and the time until the pain be-
came intolerable was measured. The tolerance time to cold
stress significantly increased after administration of KRG
compared to the placebo and nifedipine. However, the
measurement of the tolerance time to cold stress used in
the previous study is a subjective assessment tool.
The aim of the current study is to evaluate the efficacy
of KRG on CHHF by using an objective assessment tool,
infrared thermography. The hypothesis is that KRG will
reduce CHHF more effectively than placebo after eight
weeks of administering either KRG or placebo. The out-
come measures include changes of skin temperature and
the visual analogue scale (VAS) scores of CHHF, the recov-
ery rate (RR) of skin temperature by the cold stress test
(CST) of the hands, the distal-dorsal difference (DDD) of
the hands, power variables of heart rate variability (HRV),
and the 36-item short form health survey (SF-36).
Methods/Design
Trial design
This trial is a randomized, double-blind, placebo-controlled
trial in 80 CHHF patients. The trial will be implemented atKyung Hee University Hospital at Gangdong in Seoul,
Korea. The participants will take either KRG or placebo for
eight weeks, after which they will be followed-up for four
weeks. During the administration period, six capsules of
500 mg KRG or placebo will be provided twice a day (one
hour after breakfast and dinner). A flow chart of the entire
trial is shown in Figure 1.
Participants
Inclusion criteria
The patients who meet all threeof the following inclu-
sion criteria items will be included:
(1)Females aged 16 to 60 years
(2)Females complaining of CHHF
(3)A thermal difference greater than 0.3°C between the
palm and the upper arm
Exclusion criteria
Patients who report the following conditions will be
excluded:
(1)Skin ailments, radiculopathy, thrombophlebitis and
injuries affecting infrared imaging
(2)Alcohol abuse or alcoholism
(3)A history of cancer within the past five years
(4)Severe depression or mental illness
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thrombolytic agents
(6) Pregnant or breastfeeding
(7) Severe heart, pulmonary, hepatic and renal diseases
(assessed by self-reporting and a blood test at the
screening visit)
(8) Allergies to KRG or ginseng
(9) Ingestion of herbal medicine or nutritional
supplements within a week before participation
(10) Participation in another clinical trial within the
past three months
Interventions
The KRG (Korean Red Ginseng powder capsule®) was
manufactured by Korea Ginseng Corporation (Seoul,
Korea) from the root of six-year-old Panax ginseng C.A.
Meyer (family Araliaceae) harvested in Korea. The raw
ginseng was cultivated and managed by Good Agricul-
tural Practices established by the Rural Development
Administration. The manufacture of KRG was processed
according to Korean Good Manufacturing Practices and
permitted and regulated by the Korean Food and Drug
Administration. KRG was made by steaming fresh gin-
seng at 90 to 100°C for three hours, followed by drying
at 50 to 80°C. KRG capsules containing KRG powder
were prepared from ground red ginseng (KRG capsule,
500 mg/capsule). A total of 3 g of KRG powder contained
2 g of carbohydrates and 1 g of protein. The capsule was
made of hydroxypropyl methylcellulose, pectin, purified
water, sucrose fatty acid ester, glycerin, calcium gluconate
and glacial acetic acid. KRG was analyzed by high-
performance liquid chromatography. KRG contained the
following active compounds: -Rb1, 5.61 mg/g; -Rb2, 2.03
mg/g; -Rc, 2.20 mg/g; -Rd, 0.39 mg/g; -Re, 1.88 mg/g; -Rf,
0.89 mg/g; -Rg1, 3.06 mg/g; -Rg2(s), 0.15 mg/g; -Rg3(r),
0.08 mg/g; -Rg3(s), 0.17 mg/g; -Rh1, 0.30 mg/g, and other
minor ginsenosides. The standard chemical components in
KRG were the total amount of Rb1 and Rg1 (6 mg/g). The
examination of the remaining agricultural chemical was
also conducted. The tolerance limit for pesticide residue of
KRG was 0.5 mg/kg according to the regulation of Korean
Food and Drug Administration. The voucher specimens
were kept at the laboratory of Korea Ginseng Corporation
(Seoul, Korea). The lot number of KRG that will be used in
our trial is 30032005.
The participants assigned to the KRG group will be re-
quired to take six capsules of 500 mg KRG twice a day
(one hour after breakfast and dinner), accounting for
a total of 6 g in a day. The dosage of KRG was de-
termined based on the total amount of Rb1 and Rg1,
according to Korean Food Standards Codex. The partici-
pants assigned to the placebo group will take placebo
capsules similar to the color, flavor and scent of KRG.
Placebo was made of cornstarch, natural coloring (BrownCG-11771, JEY’s F.I. Inc., Sungnam Korea), brown cara-
mel coloring (Bolak Co., Hwasong Korea) and red gin-
seng flavor (C80509, French Korean Aromatics Co.,
Yongin Korea). The lot number of placebo that will be
used in our trial is 30032006. Samples of the placebo
were also kept at the Korea Ginseng Corporation (Seoul,
Korea). After several attempts, a placebo that could not
be distinguished from the real KRG by 20 healthy persons
was successfully produced. Besides, at the end of the
study, all participants will be asked whether the ex-
perimental agents that they had taken were real or pla-
cebo in order to evaluate the success of blinding. In
addition, the patients will be given a diary, which they
will be asked to fill in twice a day, after taking KRG or
placebo. The diary will be used to check their compliance
to the administration. The patients’ data will be excluded
from the per-protocol analysis unless their compliance
rate is more than 70%.
Objectives
The objectives of the current study are (1) to evaluate
the efficacy of KRG on CHHF and (2) to establish basic




The primary outcome is a change of skin temperature in
the hands between baseline (visit 2) and after treatment
(visit 4). The skin temperature will be obtained by infra-
red thermography. For the infrared thermography exam-
ination, the patient will be asked to avoid hot showers,
hot packs, smoking, exercise, acupuncture and stimulants
such as caffeine for two hours before the examination.
The patient will be acclimatized to room temperature
(25 ± 1°C) for 15 minutes and seated comfortably on a
chair without physiological or psychological stress. Sub-
sequently, the patient will stand in an anatomical posture.
Thermal images of the palm and the upper arm will be
obtained to assess cold hypersensitivity in the hands. The
difference between the palm and the upper arm, which is
related to the severity of cold hypersensitivity in the
hands, will then be calculated.
Secondary outcome
The secondary outcomes include the VAS scores of cold
hypersensitivity in the hands, change of skin temperature
and the VAS scores of cold hypersensitivity in the feet,
RR of the skin temperature by the CST of the hands, the
DDD of the hands, power variables of HRV, and the
SF-36 between the baseline (visit 2) and after the treat-
ment (visit 4). A 100-mm VAS measurement will be used
to assess the severity of CHHF. The VAS scores will be
rounded to the nearest integer in millimeters.
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after cold stress. The patient will be seated and the base-
line thermal images of the dorsum of both hands will
be acquired with infrared thermography. Subsequently,
both hands will be submerged up to the wrist in cold
water (20°C) for a period of one minute. The hands will
then be taken out of the cold water and will be carefully
wiped and dried with a dry towel. Thermal images of the
dorsum of both hands will be obtained immediately after
immersion and six minutes later. The RR of the skin
temperature at six minutes will be calculated as follows:
RR ¼ T6−T0ð Þ= Tbase−T0ð Þ  100 %ð Þ
Tbase: baseline skin temperature
T0: skin temperature immediately after cold stress
T6: skin temperature six minutes after cold stress
Recently, the thermographic DDD has been used as a
parameter to evaluate the severity of vasoconstriction
[17,18]. The DDD was calculated by subtracting the
temperature of the finger from that of the dorsum [19].
Therefore, the DDD is considered positive if the finger is
colder than the dorsum, and a high DDD indicates se-
vere CHHF.
HRV is used to study the activity of the autonomic
nervous system indirectly. Low-frequency (LF) power is
thought to be strongly related to sympathetic nerve sys-
tem activity and correlates with the regulation of blood
pressure and peripheral vascular tone. High-frequency
(HF) power reflects sinus arrhythmia and breathing ac-
tivity and is strongly based on parasympathetic nerve
system activity [20]. The ratio of LF to HF power is
commonly interpreted as an indicator of the relative bal-
ance between sympathetic and parasympathetic activity,
with higher ratios corresponding to higher relative sym-
pathetic activity [21]. The total power is not a specific
indicator of a particular type of autonomic nervous sys-
tem expression, but is rather an indicator of the total
amount of variability, which includes all of the different
possible influences on heart rate variation [20].
CHHF may lower quality of life by interfering with
daily life and restricting activities in the cold environ-
ment. Therefore, improving quality of life is another im-
portant goal in the treatment of CHHF. The SF-36 is a
generic instrument to measure health-related quality of
life and is widely used to survey physical and emotional
health. The validated Korean version of SF-36 that will
be used in this study was provided by the Health Assess-
ment Laboratory (Boston, MA, USA). It consists of 36
questions grouped into eight dimensions: physical func-
tion (10 items), role limitations owing to physical health
problems (4 items), bodily pain (2 items), general health
perception (6 items), energy and vitality (4 items), socialfunction (2 items), role limitations owing to emotional
problems (3 items) and mental health (5 items). The
number of questions for each health concept ranges from
2 to 10, and the number of response options per question
is either two (yes or no) or six (none, very mild, mild,
moderate, severe or very severe). Each of the dimension
scores are expressed as a value between 0 and 100, with
higher scores representing better health status [22].
Safety assessment
All participants will be asked to record any adverse
events in a diary during the administration and the
follow-up period. All adverse events will be described in
the case report form (CRF). The complete blood count
(CBC), erythrocyte sedimentation rate (ESR), liver func-
tion test and renal function test will be assessed to deter-
mine the safety of the treatments at the completion of
KRG or placebo administration. These analyses will be
performed at an accredited laboratory. All values de-
tected in the laboratory will be recorded by the investi-
gator in the CRF.
Sample size
This trial has a pilot characteristic to evaluate the effi-
cacy of KRG on CHHF by using infrared thermography.
Although there was no previous study that is the same
in design, we calculated the sample size on the basis of a
study that used similar variables. The previous study
measured the tolerance time to cold stress to assess the
efficacy of KRG on CHHF using a two-sided test, yield-
ing a 5% significance level [16]. The formula for estimat-
ing the sample size is as follows:
nt ¼ nc ¼ Zα=2 þ Zβ
 2




In the previous study, the tolerance time to cold stress
prolonged 0.35 minute in the KRG group compared with
the control group (μt-μc), and a mean standard deviation
(σ) was 0.84. In our study, the ratio (λ) of KRG to pla-
cebo is 1:1. With an 80% power (1-β) and a 5% signifi-
cance level (α), assuming μt-μc = 0.35 and σ = 0.84, a
sample size of nt = nc = 32 patients per group is needed
(nt, number of patients in KRG group; nc, number of pa-
tients in placebo group). Anticipating a drop-out rate of
approximately 20%, the total sample size should be more
than 80 women.
Randomization
Randomization will be performed by an independent
statistician by generating allocation numbers using a
randomization allocation program. The participants will
not be stratified. They will randomly be assigned into
KRG and placebo groups at a 1:1 ratio. The investigator
will be subsequently notified of the number assigned to
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dom number at their second visit. The allocation table
of participants will be kept by an independent statisti-
cian until the end of the study.
Blinding
The patients will be blinded to the treatment that they
are provided. The investigator and clinical pharmacist
will be also blinded to the randomization. Only the inde-
pendent statistician will be aware of the randomization.
Ethical approval
The protocol of this trial has been approved by the insti-
tutional review board (IRB) and the ethics committee of
Kyung Hee University Hospital at Gangdong, Seoul,
Korea. The permission number of this study is KHNMC-
OH-IRB 2012–004 and the protocol identification number
on ClinicalTrials.gov is NCT01664156. Written informed
consent will be obtained from all participants prior to
enrollment, and patients will be given adequate time to
declare if they wish to participate before signing the con-
sent form.
Recruitment
Information will be sent by short message service (SMS)
to patients with CHHF who were previously identified at
the Kyung Hee University Hospital at Gangdong. Public
advertisements will be placed in the newspaper and
homepage of the hospital to recruit participants. Posters,
brochures and banners will be placed inside the hospital.
Concomitant therapy
During the clinical trial, patients will be prohibited from
taking any kind of drugs or therapies that might affect
symptoms related to CHHF. These include herbal medi-
cines, acupuncture, moxibustion, cupping and infrared
treatment. Furthermore, the patients will be prohibited
from taking hypertensive or diabetic medications and
thrombolytic agents that affect vascular or endothelial
functions. However, the patients will be permitted to
take medications that would not affect CHHF. For ex-
ample, medications for a common cold, stomachache,
diarrhea and menstrual pain will be allowed.
Statistical analysis
An independent statistician will perform the statistical
analyses of all data in a blinded manner. An efficacy ana-
lysis will be performed for both ITT (intention-to-treat)
and PP (per-protocol) data set. Baseline characteristics
such as age and body mass index (BMI) between the two
groups will be compared using independent t-test or chi
square test. The target variables for analysis in this study
include the following: (1) change of skin temperature
and VAS scores of cold hypersensitivity in the hands;(2) change of skin temperature and VAS scores of cold
hypersensitivity in the feet; (3) RR of the skin temperature
by the CST of the hands; (4) the DDD of the hands;
(5) power variables of HRV; and (6) the SF-36. All values
will be presented as mean ± SD. The paired t-test will be
used to compare data between the baseline (visit 2) and
after the treatment (visit 4) in each group. Comparison be-
tween the two groups will be performed using independ-
ent t-test at each time. If there are significant differences
between the two groups at the baseline, we will compare
the variables using ANCOVA. All statistical analyses of
data will be performed by using SPSS version 17.0 (SPSS
Inc., Chicago, IL), with P- values <0.05 representing statis-
tical significance.
Discussion
CHHF cannot be dissociated from Raynaud’s phenomenon
(RP). A diagnosis of RP can be made when color changes
occur in the skin of the digits of the hands and feet in re-
sponse to cold temperatures or emotional stress [23]. RP
is known to be caused by a transient cession of blood flow
to the digits of the hands or feet [24] and is associated
with various diseases, such as rheumatoid arthritis, sclero-
derma, dermatomyositis, hypertension and migraine [25].
However, RP can occur in the absence of these disorders,
which is referred to as primary RP [26]. Although the
pathophysiology of primary RP remains poorly under-
stood, increases in sympathetic receptor activity in blood
vessels, endothelial dysfunction and some central thermo-
regulatory defects have been suggested to contribute to
the development of primary RP [24].
A survey was conducted regarding the prevalence of
RP among 1,008 outpatients who complained of abnor-
mal sensory symptoms in the hands and feet. The most
common abnormal sensory symptoms, in order of de-
scending frequency, were tingling, coldness and pain. Of
the 510 patients (52%) who answered “yes” to the ques-
tion, “Are your extremities unusually sensitive to cold?”,
290 patients (43%) showed RP [27]. These results sug-
gest that CHHF, a conventional circulatory disorder, may
be regarded as latent RP. Thus, it can be said that CHHF
is RP without color changes of the hands and feet.
Infrared thermography, which has been used as a non-
invasive investigative tool in medicine since the 1960s,
can easily assess local differences in skin temperature.
Infrared thermography is an easily applicable, well-
established imaging method that can be used to create
temperature maps of the skin with satisfying reproducibil-
ity [28,29]. Since cutaneous temperature depends on local
blood perfusion and thermal tissue properties, infrared
imaging provides important indirect information concern-
ing circulation, thermal properties, and the thermoregula-
tory function of cutaneous tissues [30]. The subjective
estimation of finger temperature has been shown to be
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red thermography [31].
For the diagnosis of cold hypersensitivity in the hands,
thermographic measurements will be performed at two
paired areas (the palm and upper arm). A diagnostic
cut-off value for cold hypersensitivity in the hands was
determined in a previous study. When the criterion for
the thermal difference between the palm and the upper
arm was set as greater than 0.3°C, the sensitivity and the
specificity of the test were 94.0% and 90.0%, respectively
[4]. In the current study, we will diagnose CHHF accord-
ing to this cut-off value.
The CST is applied to exposed skin areas with im-
paired thermoregulation [32]. The CST reportedly has
high sensitivity and specificity for RP in comparison with
healthy control subjects [33]. In addition, the CST was
shown to have good sensitivity, specificity, and positive
and negative predictive values for the diagnosis of digital
vasospasm in patients with hand-arm vibration syndrome
[34]. A previous study demonstrated a significant negative
correlation between the RR of finger temperature after cold
stress and VAS scores [35]. Therefore, RR after cold stress
would be a good indicator for evaluating CHHF.
Among other methods, the measurement of skin
temperature with the CST has been reported to be a
good indicator of sympathetic responses [36], and has
been used to evaluate central autonomic and peripheral
vascular responses [37]. Cold stimulation increases sym-
pathetic activity and the removal of the extremities from
a cool environment results in prompt rewarming in the
healthy subjects, with an RR of over 80% at five minutes.
Therefore, a reduced RR indicates exaggerated sympa-
thetic nerve function. According to previous works, a
RR of <80% is considered clinically meaningful and sug-
gests increased sympathetic nerve activities [38].
The sympathetic nervous system plays a major role in
the regulation of cutaneous blood flow [39]. Therefore,
sympathetic dysregulation has been hypothesized to be a
factor in the genesis of RP. The exaggerated digital vaso-
constrictor responses to cold, emotional stress, and
postural changes [40] and the efficacy of both local
anesthesia and sympathetic blockade in controlling vaso-
constriction of RP [41] are consistent with a hypothesis
of sympathetic over-activity. In a clinical examination,
HRV spectrum analysis revealed significantly higher LF
values in the RP group compared with the control group
[42]. Another trial revealed relatively more sympathetic
nerve system expression and less parasympathetic ex-
pression in a slow rewarming group after cold exposure
compared to a normal group. Lower values were ob-
served for all parameters after cold weather training for
15 months, and this was particularly evident for sympa-
thetic nerve system expression, as indicated by lower
LF values [43]. In the current study, we will evaluateautonomic nervous activity after the administration
of KRG by using HRV.
Controversy exists in the literature regarding the effect
of ginseng on autonomic nervous activity. Wild ginseng
pharmacopuncture in healthy adults tended to activate
the autonomic nervous system, particularly the sympa-
thetic nervous system [44]. Another clinical trial showed
higher parasympathetic and lower sympathetic activity
modulation after the administration of Kampo including
ginseng [45]. However, the investigators used wild gin-
seng pharmacopuncture or Kampo (a mixture of gin-
seng, oriental bezoar and glycyrrhiza), not ginseng alone.
The current study is the first trial to evaluate autonomic
nervous activity through the oral administration of KRG.
The DDD was shown to be a valuable parameter in
discriminating between patients with primary RP and
secondary RP due to systemic sclerosis. Previously, a
DDD >1°C in any finger at room temperature was con-
sidered a specific indicator of underlying structural vascu-
lar disease [19]. Because the DDD is used as a parameter
to evaluate the severity of vasoconstriction, the severity of
CHHF can be measured by the DDD.
Although CHHF is poorly defined medically, com-
plaints of CHHF are common in Asian women. Never-
theless, few studies have been conducted regarding the
diagnosis and treatment of CHHF. The current study is
the first trial to evaluate the efficacy of KRG on CHHF
by using infrared thermography. We anticipate that this
trial will provide basic evidence regarding CHHF and
that the protocol for this trial will be a reference for de-
signing further clinical trials.
Trial status
The study was designed in 2012 and the first participant
was randomized on 15 October 2012. Recruitment for this
study is ongoing.
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